FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014574900> ?p ?o ?g. }

• W2014574900 endingPage "298" @default.
• W2014574900 startingPage "293" @default.
• W2014574900 abstract "Objective To evaluate a cohort of United States–based urology practices for patterns related to screening, diagnosis, and treatment of bone metastases in men with castration-resistant prostate cancer. Methods Chart audits at 15 community-based urology group practices were conducted in the United States. Patient charts were eligible for study inclusion and review if they had documented bone metastasis secondary to castration-resistant prostate cancer. Data abstracted include site and patient demographics, diagnosis patterns, and bone metastases treatment between July 2006 and July 2009. A sample of approximately 10 charts per practice was used, starting with the most recent patient who met eligibility requirements. Results Eligible patients (n = 147) from 15 practices had a mean (SD) age of 67.8 (9.3) years at prostate cancer diagnosis and 72.5 (8.6) years at diagnosis of bone metastasis. Bone metastasis occurred 31.3 months (median) after cancer diagnosis. Seventy-three percent (n = 108) of patients had multiple bone metastases, and 82% (n = 120) had bone metastases in weight-bearing bones at last follow-up. Intravenous bisphosphonates were administered to 49% (72/147) of patients, with 97% (70/72) receiving zoledronic acid. Conclusion Among patients with castration-resistant prostate cancer and documented bone metastases, approximately one half received intravenous zoledronic acid. This suggests that the other half of patients with bone metastases from prostate cancer remained undertreated for the prevention of skeletal complications based on National Comprehensive Cancer Network guidelines during the study time period. To evaluate a cohort of United States–based urology practices for patterns related to screening, diagnosis, and treatment of bone metastases in men with castration-resistant prostate cancer. Chart audits at 15 community-based urology group practices were conducted in the United States. Patient charts were eligible for study inclusion and review if they had documented bone metastasis secondary to castration-resistant prostate cancer. Data abstracted include site and patient demographics, diagnosis patterns, and bone metastases treatment between July 2006 and July 2009. A sample of approximately 10 charts per practice was used, starting with the most recent patient who met eligibility requirements. Eligible patients (n = 147) from 15 practices had a mean (SD) age of 67.8 (9.3) years at prostate cancer diagnosis and 72.5 (8.6) years at diagnosis of bone metastasis. Bone metastasis occurred 31.3 months (median) after cancer diagnosis. Seventy-three percent (n = 108) of patients had multiple bone metastases, and 82% (n = 120) had bone metastases in weight-bearing bones at last follow-up. Intravenous bisphosphonates were administered to 49% (72/147) of patients, with 97% (70/72) receiving zoledronic acid. Among patients with castration-resistant prostate cancer and documented bone metastases, approximately one half received intravenous zoledronic acid. This suggests that the other half of patients with bone metastases from prostate cancer remained undertreated for the prevention of skeletal complications based on National Comprehensive Cancer Network guidelines during the study time period." @default.
• W2014574900 created "2016-06-24" @default.
• W2014574900 creator A5036003731 @default.
• W2014574900 creator A5037707751 @default.
• W2014574900 creator A5044778501 @default.
• W2014574900 creator A5076430463 @default.
• W2014574900 creator A5088518998 @default.
• W2014574900 date "2012-08-01" @default.
• W2014574900 modified "2023-09-25" @default.
• W2014574900 title "Treatment Patterns in Patients With Prostate Cancer and Bone Metastasis Among US Community-based Urology Group Practices" @default.
• W2014574900 cites W1573292320 @default.
• W2014574900 cites W170508594 @default.
• W2014574900 cites W1975577875 @default.
• W2014574900 cites W1986064336 @default.
• W2014574900 cites W2022729666 @default.
• W2014574900 cites W2030985630 @default.
• W2014574900 cites W2069876598 @default.
• W2014574900 cites W2098180445 @default.
• W2014574900 cites W2104923745 @default.
• W2014574900 cites W2113701976 @default.
• W2014574900 cites W2115015097 @default.
• W2014574900 cites W2167331614 @default.
• W2014574900 cites W2316372113 @default.
• W2014574900 cites W244262072 @default.
• W2014574900 doi "https://doi.org/10.1016/j.urology.2012.04.007" @default.
• W2014574900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22748612" @default.
• W2014574900 hasPublicationYear "2012" @default.
• W2014574900 type Work @default.
• W2014574900 sameAs 2014574900 @default.
• W2014574900 citedByCount "23" @default.
• W2014574900 countsByYear W20145749002013 @default.
• W2014574900 countsByYear W20145749002014 @default.
• W2014574900 countsByYear W20145749002015 @default.
• W2014574900 countsByYear W20145749002016 @default.
• W2014574900 countsByYear W20145749002017 @default.
• W2014574900 countsByYear W20145749002018 @default.
• W2014574900 countsByYear W20145749002019 @default.
• W2014574900 countsByYear W20145749002020 @default.
• W2014574900 countsByYear W20145749002021 @default.
• W2014574900 countsByYear W20145749002022 @default.
• W2014574900 crossrefType "journal-article" @default.
• W2014574900 hasAuthorship W2014574900A5036003731 @default.
• W2014574900 hasAuthorship W2014574900A5037707751 @default.
• W2014574900 hasAuthorship W2014574900A5044778501 @default.
• W2014574900 hasAuthorship W2014574900A5076430463 @default.
• W2014574900 hasAuthorship W2014574900A5088518998 @default.
• W2014574900 hasConcept C121608353 @default.
• W2014574900 hasConcept C126322002 @default.
• W2014574900 hasConcept C126894567 @default.
• W2014574900 hasConcept C143998085 @default.
• W2014574900 hasConcept C2776326535 @default.
• W2014574900 hasConcept C2777783956 @default.
• W2014574900 hasConcept C2779013556 @default.
• W2014574900 hasConcept C2780192828 @default.
• W2014574900 hasConcept C71924100 @default.
• W2014574900 hasConcept C72563966 @default.
• W2014574900 hasConceptScore W2014574900C121608353 @default.
• W2014574900 hasConceptScore W2014574900C126322002 @default.
• W2014574900 hasConceptScore W2014574900C126894567 @default.
• W2014574900 hasConceptScore W2014574900C143998085 @default.
• W2014574900 hasConceptScore W2014574900C2776326535 @default.
• W2014574900 hasConceptScore W2014574900C2777783956 @default.
• W2014574900 hasConceptScore W2014574900C2779013556 @default.
• W2014574900 hasConceptScore W2014574900C2780192828 @default.
• W2014574900 hasConceptScore W2014574900C71924100 @default.
• W2014574900 hasConceptScore W2014574900C72563966 @default.
• W2014574900 hasIssue "2" @default.
• W2014574900 hasLocation W20145749001 @default.
• W2014574900 hasLocation W20145749002 @default.
• W2014574900 hasOpenAccess W2014574900 @default.
• W2014574900 hasPrimaryLocation W20145749001 @default.
• W2014574900 hasRelatedWork W1856092259 @default.
• W2014574900 hasRelatedWork W1988873325 @default.
• W2014574900 hasRelatedWork W2324715925 @default.
• W2014574900 hasRelatedWork W2368994420 @default.
• W2014574900 hasRelatedWork W2375435548 @default.
• W2014574900 hasRelatedWork W2417724487 @default.
• W2014574900 hasRelatedWork W2784010975 @default.
• W2014574900 hasRelatedWork W3032254165 @default.
• W2014574900 hasRelatedWork W4282937734 @default.
• W2014574900 hasRelatedWork W4298087892 @default.
• W2014574900 hasVolume "80" @default.
• W2014574900 isParatext "false" @default.
• W2014574900 isRetracted "false" @default.
• W2014574900 magId "2014574900" @default.
• W2014574900 workType "article" @default.